Main Article Content
Abstract
Keywords
Article Details
-
Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:
Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
You are free to :
Share ” copy and redistribute the material in any medium or format.
Adapt ” remix, transform, and build upon the material.
References
- Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE (2000). The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 85, 883-889
- Adler RA and Hochberg MC (2003). Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163, 2619-2624
- Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman J, Reginster JY, Rozenberg S (2011). Loading and skeletal development and maintenance. Journal of Osteoporosis 2011, 1-16
- Bonewald LF (2011). The amazing osteocyte. J Bone Miner Res 26, 229-238
- Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS (2008). The cell biology of bone metabolism. J Clin Pathol 61, 577-587
- Downey PA and Siegel MI (2006). Bone biology and the clinical implications for osteoporosis. Phys Ther 86, 77-91
- Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997). A transcriptional activator of osteoblast differentiation. Cell 89, 747-754
- Dvorak J, Feddermann N, Grimm K (2006). Glucocorticosteroids in football: use and misuse. Br J Sports Med 40, 148-154
- Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA (2008). Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology 149, 146-153
- Ganong WF (2005). Review of Medical Physiology, New York, McGraw-Hill Comp, p 342-380
- García AJ and Reyes CD (2005). Bio-adhesive surfaces to promote osteoblast differentiation and bone formation. J Dent Res 84, 407-413
- Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES (2002). Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 277, 13430-13437
- Hall JE and Guyton AC (2011). Guyton and Hall Textbook of Medical Physiology, Philadelphia, Saunders/Elsevier
- Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999). Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382-4389
- Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS (2006). Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147, 5592-5599
- Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL (2006). Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116, 2152-2160
- Klein-Nulend J, Bakker AD, Bacabac RG, Vatsa A, Weinbaum S (2013). Mechanosensation and transduction in osteocytes. Bone 54, 182-190
- Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, Denhardt DT, Nakashima K, Karsenty G, Noda M (2005). Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem 280, 30192-30200
- Kumar V, Abbas AK, Fausto N (2005). Robbins and Cotran Pathologic Basic of Disease, 7th ed, Philadelphia, Elsevier, p 26-106
- Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH, Bonewald LF (2006). Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21, 466-476
- Lorenzo J, Horowitz M, Choi Y (2008). Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29, 403-440
- Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M (2003). Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83, 965-1016
- Lu NZ, Collins JB, Grissom SF, Cidlowski JA (2007). Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol Cell Biol 27, 7143-7160
- Manolagas SC (2000). Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21, 115-137
- Manolagas SC, Kousteni S, Jilka RL (2002). Sex steroids and bone. Recent Prog Horm Res 57, 385-409
- McNamara LM (2010). Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 7, 353-372
- Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003). Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144, 5441-5449
- Owen GR, Meredith DO, ap Gwynn I, Richards RG (2005). Focal adhesion quantification - a new assay of material biocompatibility? Review. Eur Cell Mater 9, 85-96
- Park SY, Avraham HK, Avraham S (2004). RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner. J Biol Chem 279, 33315-33322
- Plotkin LI, Manolagas SC, Bellido T (2007). Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J Biol Chem 282, 24120-24130
- Plotkin LI, Mathov I, Aguirre JI, Parfitt AM, Manolagas SC, Bellido T (2005). Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs. Am J Physiol Cell Physiol 289, C633-C643
- Raison CL and Miller AH (2003). When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 160, 1554–1565
- Raisz LG (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115, 3318-3325
- Riggs BL1, Khosla S, Melton LJ 3rd (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23, 279-302
- Seibel MJ (2005). Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26, 97-122
- Sherwood L (2010). Human Physiology: From Cells to Systems, 7th ed, Belmont, Brooks/Cole, Cengage Learning, p 769
- Suatmadji DW (2001). Pathogenesis of steroid-induced osteoporosis. Naskah lengkap Simposium Asma & Osteoporosis, PDPI Cabang Malang/RSUD Dr Saiful Anwar, p 41-55
- Swanson C, Lorentzon M, Conaway HH, Lerner UH (2006). Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 147, 3613-3622
- Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y (2003). Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278, 44667-44674
- Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000). Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141, 3478-3484
- Watts NB (1999). Clinical utility of biochemical markers of bone remodeling. Clin Chem 45, 1359-1368
- Weinstein RS1, Nicholas RW, Manolagas SC (2000). Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85, 2907-2912
References
Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE (2000). The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 85, 883-889
Adler RA and Hochberg MC (2003). Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163, 2619-2624
Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman J, Reginster JY, Rozenberg S (2011). Loading and skeletal development and maintenance. Journal of Osteoporosis 2011, 1-16
Bonewald LF (2011). The amazing osteocyte. J Bone Miner Res 26, 229-238
Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS (2008). The cell biology of bone metabolism. J Clin Pathol 61, 577-587
Downey PA and Siegel MI (2006). Bone biology and the clinical implications for osteoporosis. Phys Ther 86, 77-91
Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997). A transcriptional activator of osteoblast differentiation. Cell 89, 747-754
Dvorak J, Feddermann N, Grimm K (2006). Glucocorticosteroids in football: use and misuse. Br J Sports Med 40, 148-154
Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA (2008). Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology 149, 146-153
Ganong WF (2005). Review of Medical Physiology, New York, McGraw-Hill Comp, p 342-380
García AJ and Reyes CD (2005). Bio-adhesive surfaces to promote osteoblast differentiation and bone formation. J Dent Res 84, 407-413
Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES (2002). Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 277, 13430-13437
Hall JE and Guyton AC (2011). Guyton and Hall Textbook of Medical Physiology, Philadelphia, Saunders/Elsevier
Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999). Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382-4389
Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS (2006). Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147, 5592-5599
Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL (2006). Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116, 2152-2160
Klein-Nulend J, Bakker AD, Bacabac RG, Vatsa A, Weinbaum S (2013). Mechanosensation and transduction in osteocytes. Bone 54, 182-190
Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, Denhardt DT, Nakashima K, Karsenty G, Noda M (2005). Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem 280, 30192-30200
Kumar V, Abbas AK, Fausto N (2005). Robbins and Cotran Pathologic Basic of Disease, 7th ed, Philadelphia, Elsevier, p 26-106
Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH, Bonewald LF (2006). Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21, 466-476
Lorenzo J, Horowitz M, Choi Y (2008). Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29, 403-440
Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M (2003). Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83, 965-1016
Lu NZ, Collins JB, Grissom SF, Cidlowski JA (2007). Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol Cell Biol 27, 7143-7160
Manolagas SC (2000). Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21, 115-137
Manolagas SC, Kousteni S, Jilka RL (2002). Sex steroids and bone. Recent Prog Horm Res 57, 385-409
McNamara LM (2010). Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 7, 353-372
Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003). Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144, 5441-5449
Owen GR, Meredith DO, ap Gwynn I, Richards RG (2005). Focal adhesion quantification - a new assay of material biocompatibility? Review. Eur Cell Mater 9, 85-96
Park SY, Avraham HK, Avraham S (2004). RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner. J Biol Chem 279, 33315-33322
Plotkin LI, Manolagas SC, Bellido T (2007). Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J Biol Chem 282, 24120-24130
Plotkin LI, Mathov I, Aguirre JI, Parfitt AM, Manolagas SC, Bellido T (2005). Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs. Am J Physiol Cell Physiol 289, C633-C643
Raison CL and Miller AH (2003). When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 160, 1554–1565
Raisz LG (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115, 3318-3325
Riggs BL1, Khosla S, Melton LJ 3rd (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23, 279-302
Seibel MJ (2005). Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26, 97-122
Sherwood L (2010). Human Physiology: From Cells to Systems, 7th ed, Belmont, Brooks/Cole, Cengage Learning, p 769
Suatmadji DW (2001). Pathogenesis of steroid-induced osteoporosis. Naskah lengkap Simposium Asma & Osteoporosis, PDPI Cabang Malang/RSUD Dr Saiful Anwar, p 41-55
Swanson C, Lorentzon M, Conaway HH, Lerner UH (2006). Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 147, 3613-3622
Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y (2003). Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278, 44667-44674
Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000). Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141, 3478-3484
Watts NB (1999). Clinical utility of biochemical markers of bone remodeling. Clin Chem 45, 1359-1368
Weinstein RS1, Nicholas RW, Manolagas SC (2000). Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85, 2907-2912